CBX - China Biotech XYZ

An increasing number of drug candidates made in China have been out-licensed. Here are the ones aimed for approval in foreign countries. Shanghai Night ★ BL-B01D1, anti-EGFRxHER3 ADC,  SystImmune 2023.12  Announced in Ph3, BMS " $800 million in an upfront payment and up to $500 million in contingent near-term payments. SystImmune is eligible to receive additional payments of up to $7.1 billion contingent upon the achievement of certain development, regulatory and sales performance milestones for a total potential consideration of up to $8.4 billion. The companies will share certain global development expenses and profits and losses in the United States. Through its affiliates, SystImmune will retain exclusive development and commercialization rights in Mainland China, where Bristol Myers Squibb will receive a royalty on net sales. Outside the United States and Mainland China, SystImmune will receive a tiered royalty on net sales. The agreement is subject to customary clearance by